Drug intelligence / Profile preview

LY3556050 + iohexol

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

LY3556050 + iohexol is a combination used in clinical pharmacology studies, where LY3556050 is an investigational small molecule being developed by Eli Lilly for indications such as diabetic peripheral neuropathic pain. Iohexol is a non-ionic, water-soluble radiographic contrast agent most commonly used for imaging and assessment of renal function. In the context of clinical trials, iohexol is frequently administered intravenously alongside other drugs to evaluate kidney function via its pharmacokinetic properties, while LY3556050's pharmacokinetics, safety, and drug interactions are the primary investigational focus.

Other names: iohexolumWIN 39424WIN39424WIN-39424

Targets

SSTR4 (Somatostatin receptor 4)

Beyond the preview

Go deeper on LY3556050 + iohexol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3556050 + iohexol.

Explore the full profile